unknown
Stage
1
Investors
About
Developing a first-in-class small-molecule direct plasmin inhibitor intended for intravenous administration.
Explore Clotprotect Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.